Sort by
Refine Your Search
-
, pharmacovigilance, pharmacoepidemiology methods development). In general you will have opportunities to learn: Understanding of pharmacovigilance workflows; GenAI based algorithm and agent development for causality
-
. These efforts cover more than just medicines. Research Project: The aim of this research focuses on integrating FDA’s GenAI tool’s capabilities (through API calls) into the InfoViP platform while developing
-
. Research Project: The project involves using FDA’s AI tool ‘Elsa,’ which uses either Claude Sonnet or Gemini models, to develop prompts to summarize different industry submissions and validate outputs
-
storage physiology, abiotic stress resilience, flavor and nutritional quality; and development of molecular tools, pest management and plant breeding strategies. Research Project: This appointment is
-
literature and no clinical pharmacology guidance exists due to their novelty and rapid evolution. The research aims to facilitate product development, assist review decision-making, identify regulatory
-
conducts regulatory science and research activities based on quantitative approaches. Some of the responsibilities residing in DQMM include providing quantitative method support for guidance development
-
to join this development team as a fellow and learn to create, evaluate, and validate rapid, accurate, and sensitive diagnostic methods for detecting disease pathogens. The fellow will have an opportunity
-
. The Biologics Development Module (BDM) is a unique applied research laboratory space within NBAF tasked with the mission of transitioning research developments into products. The BDM operates at a BSL-2 level of
-
on developing methods for the genetic engineering of grapevine (Vitis vinifera) and potentially other plants with the goal of generating plant varieties with novel desirable traits. Combinations of tissue culture
-
to join a collaborative project with interdisciplinary research that focuses on developing mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel therapeutic approach for systemic